Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

REOPRO DIN 02216973

Status: Cancelled Post Market
Holder: JANSSEN INC
Molecule: ABCIXIMAB

Health Canada record

Active ingredient(s)ABCIXIMAB 2 MG
Dosage formSolution
RouteIntravenous
SchedulePRESCRIPTION; SCHEDULE D
ClassHuman
ATCB01AC13 ABCIXIMAB
Original market date30-Oct-1996
Current status date14-Jun-2018
SourceHealth Canada DPD

Establishment licence of the holder

Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).

No Canadian shortage report is currently matched to this DIN.

Notices of Compliance

NOCDateSubmissionReason
130622012-02-27New Drug Submission (NDS)Manufacturer name change
124852011-06-27New Drug Submission (NDS)Manufacturer name change
41751996-07-04New Drug Submission (NDS)
Request a quote for REOPRO

How to read a Canadian DIN record